JANX — Janux Therapeutics Share News
0.000.00%
Last trade - 00:00- $1.04bn
- $72.08m
- $10.00m
Janux Therapeutics jumps after upsized equity raise
Brief: Janux Therapeutics Announces Pricing Of $296.5 Million Underwritten Public Offering Of Common Stock
Brief: Janux Therapeutics Announces Proposed Public Offering Of Common Stock
U.S. STOCKS ON THE MOVE-Cava, Bank of America, Fractyl Health
U.S. STOCKS ON THE MOVE-Kroger, Sezzle, Sealed Air Corp
Janux surges on positive data from prostate cancer therapy trial
Janux Therapeutics surges on upbeat trial data for prostate cancer therapy (updated)
U.S. STOCKS ON THE MOVE-Intuitive Machines, Hims & Hers Health, Macy's
Janux Therapeutics surges as trial data for prostate cancer therapy shows promise
U.S. STOCKS ON THE MOVE-Crypto stocks, Lowe's, Janux Therapeutics
Janux Therapeutics surges on positive data from prostate cancer therapy trial
Brief: Janux Therapeutics Inc - Janx008 Data Shows No Crs Greater Than Grade 1 Observed In Any Cohort
Brief: Janux Therapeutics Anticipates Providing An Update On Doses For Expansion In Second Half Of 2024
Brief: Janux Therapeutics Q3 Basic EPS USD -0.25
Brief: Janux Therapeutics Q2 Basic EPS USD -0.42
Brief: Janux Therapeutics Announces Positive Interim Clinical Data From Phase 1A Dose Escalation For PSMA-TRACTr JANX007
Brief: Janux Therapeutics Announces Pricing Of $60 Mln Underwritten Offering Of Common Stock And Pre-Funded Warrants
Brief: Janux Therapeutics Names Zachariah Mciver Vice President, Clinical Development
Brief: Janux Therapeutics Q1 collaboration revenue USD 2.048 million